American Capital Management Inc. Makes New $49.26 Million Investment in Repligen Corporation $RGEN

Key Points

• American Capital Management acquired 361,055 Repligen shares worth approximately $49.26 million, making RGEN its 20th-largest holding and representing a 0.64% stake. Institutional investors collectively own 97.64% of the company.
• Analyst sentiment is broadly positive: Repligen has a consensus “Buy” rating and an average price target of $166.43, with several firms recently upgrading the stock or raising targets.
• Repligen beat quarterly expectations with adjusted EPS of $0.54 versus $0.45 estimated and revenue of $204.13 million, up 11.9% year over year. Shares opened at $180.30, near their 52-week high of $188.73, though the stock trades at a notably high P/E ratio of 246.99.

American Capital Management Inc. acquired a new position in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 361,055 shares of the biotechnology company's stock, valued at approximately $49,262,000. Repligen comprises approximately 2.2% of American Capital Management Inc.'s holdings, making the stock its 20th largest holding. American Capital Management Inc. owned 0.64% of Repligen at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in RGEN. ABS Investment Management LLC purchased a new stake in Repligen in the 2nd quarter valued at about $191,016,000. Rachor Investment Advisory Services LLC acquired a new position in shares of Repligen in the 4th quarter worth approximately $33,000. Measured Wealth Private Client Group LLC purchased a new position in shares of Repligen during the 3rd quarter worth approximately $29,000. Los Angeles Capital Management LLC acquired a new stake in Repligen in the 4th quarter valued at approximately $36,000. Finally, Farther Finance Advisors LLC increased its holdings in Repligen by 61.8% in the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company's stock valued at $55,000 after purchasing an additional 128 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CFO Jason K. Garland sold 733 shares of the stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the sale, the chief financial officer directly owned 19,359 shares of the company's stock, valued at approximately $2,807,055. This represents a 3.65% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.60% of the company's stock.

Analyst Ratings Changes

Several brokerages have commented on RGEN. Benchmark raised shares of Repligen from a "hold" rating to a "buy" rating and set a $185.00 price target for the company in a research report on Tuesday, July 7th. Zacks Research raised Repligen from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 30th. Evercore reiterated an "outperform" rating and issued a $160.00 price objective on shares of Repligen in a research note on Monday, July 6th. Wells Fargo & Company boosted their target price on Repligen from $180.00 to $185.00 and gave the stock an "overweight" rating in a research note on Thursday, July 30th. Finally, Wolfe Research initiated coverage on Repligen in a report on Tuesday, June 2nd. They set an "outperform" rating and a $145.00 price target on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $166.43.

Repligen Price Performance

Shares of NASDAQ:RGEN opened at $180.30 on Thursday. The company has a 50-day simple moving average of $150.11 and a 200-day simple moving average of $132.51. Repligen Corporation has a one year low of $100.99 and a one year high of $188.73. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.64 and a current ratio of 9.05. The stock has a market capitalization of $10.18 billion, a price-to-earnings ratio of 246.99, a PEG ratio of 3.32 and a beta of 1.03.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The company had revenue of $204.13 million for the quarter, compared to analysts' expectations of $201.59 million. During the same period in the previous year, the company posted $0.26 EPS. Repligen's revenue was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, analysts predict that Repligen Corporation will post 2.06 EPS for the current year.

About Repligen

Repligen Corporation NASDAQ: RGEN is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen's offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company's core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source